Uptake and acceptability of a mainstreaming model of hereditary cancer multigene panel testing among patients with ovarian, pancreatic, and prostate cancer.

ABSTRACT:

Purpose

To address demands for timely germline information to guide treatments, we evaluated experiences of patients with ovarian, pancreatic, and prostate cancer with a mainstreaming genetic testing model wherein multigene panel testing was ordered by oncologists with standardized pretest patient education, and genetic counselors delivered results and post-test genetic counseling via telephone.

Methods

Among 1,203 eligible patients, we conducted a prospective single-arm study to examine patient uptake and acceptability (via self-report surveys at baseline and three weeks and three months following result return) of this mainstreaming model.

Results

Only 10% of eligible patients declined participation. Among 1,054 tested participants, 10% had pathogenic variants (PV),

SUBMITTER: Hamilton JG 

PROVIDER: S-EPMC8556289 | biostudies-literature | 2021 Nov

REPOSITORIES: biostudies-literature